Annovis Bio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 09/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $0 | $0 | — |
| Research and development | $25.2M | $20.0M | $38.8M | $16.5M | — |
| Operating expenses | $29.7M | $26.7M | $45.0M | $25.5M | — |
| Operating income | -$29.7M | -$26.7M | -$45.0M | -$25.5M | — |
| Pretax income | — | — | -$56.2M | -$25.3M | — |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$28.9M | -$24.6M | -$56.2M | -$25.3M | — |
| Balance Sheet | |||||
| Cash and equivalents | $19.5M | $10.6M | $5.8M | $28.4M | $32.0M |
| Current assets | — | — | $10.2M | $36.0M | $37.1M |
| Total assets | $21.1M | $13.9M | $10.2M | $36.0M | $37.1M |
| Current liabilities | $3.6M | $3.9M | $4.3M | $7.7M | $2.5M |
| Total liabilities | $4.2M | $4.6M | $18.0M | $7.7M | $2.5M |
| Stockholders' equity | $16.9M | $9.3M | -$7.8M | $28.3M | $34.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$25.6M | -$21.9M | -$40.0M | -$17.3M | — |
| Stock-based compensation | $1.8M | $3.8M | $4.6M | $9.2M | — |
Shares outstanding 34.6M · Free float 85.5%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.